11.06.14
San Diego, Calif.-based Dexcom Inc., which makes continuous glucose monitoring (CGM) technology, has gained U.S. Food and Drug Administration approval for its Dexcom G4 Platinum CGM software. The program feature an advanced algorithm used in artificial pancreas research globally, and is made for use with the Dexcom G4 Platinum CGM system. The software will be available for free for patients using the system.
“Patients will be able to go online and download the software, or they will receive the software preloaded onto their Dexcom receiver with new orders,” said CEO Terrence Gregg. “This latest software enhancement to the Dexcom G4 Platinum will make the performance level comparable to episodic blood glucose finger sticks; this is a significant step in the evolution of CGM becoming the standard-of-care over blood glucose meters for people with diabetes.”
Now, Dexcom G4 Platinum has a single-digit MARD (mean absolute relative difference) measurement, below 10 percent. MARD is the standard industry measurement of accuracy, where a lower MARD reflects higher accuracy. With the new software, healthcare providers, patients and caregivers will now have glucose readings from a sensor that are the closest yet to lab accuracy, the company claims. The combination of the new software with the CGM advantages of real-time trends, speed and direction provides a complete picture of the patient’s glucose activity.
Dexcom makes continuous glucose monitoring systems for use by diabetes patients, as well as blood glucose monitoring systems used by healthcare providers in hospital critical care settings.
“Patients will be able to go online and download the software, or they will receive the software preloaded onto their Dexcom receiver with new orders,” said CEO Terrence Gregg. “This latest software enhancement to the Dexcom G4 Platinum will make the performance level comparable to episodic blood glucose finger sticks; this is a significant step in the evolution of CGM becoming the standard-of-care over blood glucose meters for people with diabetes.”
Now, Dexcom G4 Platinum has a single-digit MARD (mean absolute relative difference) measurement, below 10 percent. MARD is the standard industry measurement of accuracy, where a lower MARD reflects higher accuracy. With the new software, healthcare providers, patients and caregivers will now have glucose readings from a sensor that are the closest yet to lab accuracy, the company claims. The combination of the new software with the CGM advantages of real-time trends, speed and direction provides a complete picture of the patient’s glucose activity.
Dexcom makes continuous glucose monitoring systems for use by diabetes patients, as well as blood glucose monitoring systems used by healthcare providers in hospital critical care settings.